A Humanized Monoclonal Antibody against Respiratory Syncytial Virus (Palivizumab) Inhibits RSV-Induced Neurogenic-Mediated Inflammation in Rat Airways

This publication has 16 references indexed in Scilit:

• Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years
  The Lancet, 1999
• Syndrome of Periodic Fever, Aphthous stomatitis, Pharyngitis, and Adenitis (PFAPA)—What it isn’t. What is it?
  The Journal of Pediatrics, 1999
• Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants
  Pediatrics, 1998
• Replication-deficient adenoviral vector for gene transfer potentiates airway neurogenic inflammation.
  American Journal of Respiratory Cell and Molecular Biology, 1997
• Reduction of Respiratory Syncytial Virus Hospitalization Among Premature Infants and Infants With Bronchopulmonary Dysplasia Using Respiratory Syncytial Virus Immune Globulin Prophylaxis
  Pediatrics, 1997
• Tachykinin Peptides, Receptors, and Peptidases in Airway Disease
  Experimental Lung Research, 1995
• Neurogenic Inflammation and Asthma
  Journal of Asthma, 1992
• Glucocorticoids inhibit neurogenic plasma extravasation and prevent virus-potentiated extravasation in the rat trachea.
  Journal of Clinical Investigation, 1990
• The development of monoclonal antibodies to respiratory syncytial virus and their use in diagnosis by indirect immunofluorescence
  Journal of Medical Virology, 1985
• Vascular protein leakage in various tissues induced by substance P, capsaicin, bradykinin, serotonin, histamine and by antigen challenge
  Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1983